scholarly journals Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

2016 ◽  
Vol 22 (10) ◽  
pp. 1732-1740 ◽  
Author(s):  
David Mesher ◽  
Kate Soldan ◽  
Matti Lehtinen ◽  
Simon Beddows ◽  
Marc Brisson ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Population Level ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Programs

scholarly journals Evaluating Human Papillomavirus Vaccination Programs

2004 ◽  
Vol 10 (11) ◽  
pp. 1915-1923 ◽  
Author(s):  
Al V. Taira ◽  
Christopher P. Neukermans ◽  
Gillian D. Sanders
Keyword(s):  
Human Papillomavirus ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Programs

scholarly journals Investigating Stakeholder Attitudes and Opinions on School-Based Human Papillomavirus Vaccination Programs

2015 ◽  
Vol 85 (5) ◽  
pp. 289-298 ◽  
Author(s):  
Jessica A. Nodulman ◽  
Randall Starling ◽  
Alberta S. Kong ◽  
David B. Buller ◽  
Cosette M. Wheeler ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Programs ◽  
School Based ◽  
Stakeholder Attitudes

scholarly journals Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects

2020 ◽  
Author(s):  
Joske Hoes ◽  
Petra J Woestenberg ◽  
Johannes A Bogaards ◽  
Audrey J King ◽  
Hester E de Melker ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
The Netherlands ◽  
Hpv Vaccination ◽  
Population Level ◽  
Second Order ◽  
Vaccine Uptake ◽  
Heterosexual Men ◽  
Hpv 16 ◽  
Vaccination Programs ◽  
Hpv Types

Abstract Background Human papillomavirus (HPV) vaccination programs achieve substantial population-level impact, with effects extending beyond protection of vaccinated individuals. We assessed trends in HPV prevalence up to 8 years postvaccination among men and women in the Netherlands, where bivalent HPV vaccination, targeting HPV types 16/18, has been offered to (pre)adolescent girls since 2009 with moderate vaccination coverage. Methods We used data from the PASSYON study, a survey initiated in 2009 (prevaccination) and repeated biennially among 16- to 24-year-old visitors of sexual health centers. We studied genital HPV positivity from 2009 to 2017 among women, heterosexual men, and unvaccinated women using Poisson generalized estimating equation models, adjusted for individual- and population-level confounders. Trends were studied for 25 HPV types detected by the SPF10-LiPA25 platform. Results A total of 6354 women (64.7% self-reported unvaccinated) and 2414 heterosexual men were included. Percentual declines in vaccine types HPV-16/18 were observed for all women (12.6% per year [95% confidence interval {CI}, 10.6–14.5]), heterosexual men (13.0% per year [95% CI, 8.3–17.5]), and unvaccinated women (5.4% per year [95% CI, 2.9–7.8]). We observed significant declines in HPV-31 (all women and heterosexual men), HPV-45 (all women), and in all high-risk HPV types pooled (all women and heterosexual men). Significant increases were observed for HPV-56 (all women) and HPV-52 (unvaccinated women). Conclusions Our results provide evidence for first-order herd effects among heterosexual men against HPV-16/18 and cross-protective types. Additionally, we show second-order herd effects against vaccine types among unvaccinated women. These results are promising regarding population-level and clinical impact of girls-only bivalent HPV vaccination in a country with moderate vaccine uptake.

Human Papillomavirus Vaccination in the Prevention of Cervical Neoplasia

2009 ◽  
Vol 19 (9) ◽  
pp. 1610-1613 ◽  
Author(s):  
Katharine Astbury ◽  
Michael J. Turner
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Disease Incidence ◽  
Developed Countries ◽  
Cervical Neoplasia ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Programs ◽  
Screening Programs ◽  
Hpv 18

Cervical cancer remains a major cause of morbidity and mortality for women worldwide. Although the introduction of comprehensive screening programs has reduced the disease incidence in developed countries, it remains a major problem in the developing world. The recent licensing of 2 vaccines against human papillomavirus (HPV) type 16 and HPV-18, the viruses responsible for 70% of cervical cancer cases, offers the hope of disease prevention. In this article, we review the role of HPV in the etiology of cervical cancer and the evidence to support the introduction of vaccination programs in young women and discus the potential obstacles to widespread vaccination. In addition, we discuss the issues that remain to be elucidated, including the potential need for booster doses of the vaccine and the role of concomitant vaccination in men.

Sign in / Sign up

Export Citation Format

Share Document